公开(公告)号：US10357570B2

公开(公告)日：2019-07-23

申请号：US15897093

申请日：2018-02-14

申请人： Heron Therapeutics, Inc.

发明人： Steven Y. Ng ,  Hui-Rong Shen ,  Jorge Heller

IPC分类号： A61K31/439 ,  A61K31/435 ,  A61K31/46 ,  A61K31/416 ,  A61K47/30 ,  A61P1/08 ,  C07D319/04 ,  A61K47/34 ,  A61K8/85 ,  A61K8/86 ,  A61K9/00 ,  A61K9/06 ,  A61K9/16 ,  A61K31/765 ,  A61K47/10 ,  A61Q19/00 ,  A61K31/445 ,  A61K31/573 ,  A61K45/06 ,  A61Q15/00 ,  A61Q17/04

摘要： A semi-solid delivery vehicle contains a polyorthoester and an excipient, and a semi-solid pharmaceutical composition contains an active agent and the delivery vehicle. The pharmaceutical composition may be a topical, syringable, or injectable formulation; and is suitable for local delivery of the active agent. Methods of treatment are also disclosed.

公开(公告)号：US20190142738A1

公开(公告)日：2019-05-16

申请号：US16300116

申请日：2017-05-16

申请人： DELIVRA INC.

发明人： Joseph Gabriele ,  Mikaela Teris

IPC分类号： A61K9/00 ,  A61K31/635 ,  A61K9/107 ,  A61K47/14 ,  A61K47/44 ,  A61K47/30 ,  A61K47/46 ,  A61K47/24 ,  A61K9/06 ,  A61K47/22

摘要： The present application is directed to transdermal formulations for the delivery of celecoxib to a subject for the treatment of celecoxib-responsive diseases or conditions. In particular, the transdermal formulation is an emulsion comprising an oil phase, an aqueous phase and an external phase.

公开(公告)号：US10182985B2

公开(公告)日：2019-01-22

申请号：US15317566

申请日：2015-06-11

申请人： Massachusetts Institute of Technology ,  The Brigham and Women's Hospital, Inc.

发明人： Andrew Bellinger ,  Shiyi Zhang ,  Carlo Giovanni Traverso ,  Robert S. Langer ,  Stacy Mo ,  Tyler Grant ,  Mousa Jafari ,  Dean Liang Glettig ,  Angela DiCiccio ,  Lowell L. Wood, Jr. ,  Philip A. Eckhoff

IPC分类号： A61K9/00 ,  A61K47/30 ,  C08G18/73 ,  C08G63/08 ,  C08G18/42 ,  A61K9/48 ,  A61K31/357 ,  A61K31/65 ,  A61K31/7048 ,  C08G83/00 ,  A61K47/32 ,  C08L33/02 ,  C08L33/08 ,  C08L33/14 ,  A61K47/10 ,  A61K47/34 ,  A61K47/40 ,  A61K47/42 ,  A61M31/00 ,  A61K47/58 ,  A61K47/69

摘要： Certain embodiments comprise administering a residence structure to a subject (e.g., a patient) such that the residence structure is retained at a location internal to the subject for a particular amount of time (e.g., at least about 24 hours) before being released. In certain embodiments, the structure has a modular design, combining a material configured for controlled release of therapeutic, diagnostic, and/or enhancement agents with a structural material necessary for gastric residence but configured for controlled and/or tunable degradation/dissolution to determine the time at which retention shape integrity is lost and the structure passes out of the gastric cavity. For example, in certain embodiments, the residence structure comprises a first elastic component, a second component configured to release an active substance, and, optionally, a linker. In some such embodiments, the linker may be configured to degrade.

公开(公告)号：US10159715B2

公开(公告)日：2018-12-25

申请号：US15313501

申请日：2015-05-29

申请人： HANMI PHARM. CO., LTD.

发明人： Jung Kuk Kim ,  Dae Jin Kim ,  Yong Ho Heo ,  In Young Choi ,  Sung Youb Jung ,  Se Chang Kwon

IPC分类号： A61K38/26 ,  A61K38/28 ,  A61K47/30 ,  C07K16/28 ,  A61K47/60 ,  A61K47/50 ,  A61K47/68

摘要： The present invention relates to a composition for the prevention or treatment of diabetes including a long-acting insulin conjugate and a long-acting insulinotropic peptide conjugate, and a method for treating diabetes. More specifically, combination administration of the long-acting analog conjugate and the long-acting insulinotropic peptide conjugate inhibits weight gain due to administration of insulin, and vomiting and nausea due to administration of the insulinotropic peptide, and also reduces the required doses of insulin, thereby remarkably improving drug compliance. In addition, the present invention relates to administering a pharmaceutical composition for reducing side effects of pancreatic beta cells in diabetic patients, including a long-acting insulin analog conjugate and a long-acting insulinotropic peptide analog conjugate, and to a method for reducing side effects of pancreatic beta cells in diabetic patients, including the step of administering the composition. Specifically, the present invention is characterized in reducing side effects such as abnormality in the function of pancreatic beta cells associated with the development of diabetes, reduction in the pancreatic beta cell mass, lipotoxicity, or glucotoxicity.

公开(公告)号：US09993519B2

公开(公告)日：2018-06-12

申请号：US15113823

申请日：2016-03-03

申请人： SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION ,  NANO INTELLIGENT BIOMEDICAL ENGINEERING CORPORATION CO., LTD.

发明人： Yoon Jeong Park ,  Chong-Pyoung Chung ,  Jue-Yeon Lee ,  Jin Sook Suh

IPC分类号： A61K38/00 ,  A61P35/00 ,  A61K38/10 ,  A61K9/00 ,  A61K47/30

CPC分类号： A61K38/10 ,  A61K9/00 ,  A61K47/30

摘要： The present invention relates to an anticancer composition comprising a peptide that inhibits the proliferation of cancer stem cells present in tumor tissue and that induces apoptosis of such cancer stem cells, and more particularly, to an anticancer peptide that inhibits the activity of NF-κB which is overexpressed specifically in cancer stem cells present in tumors.

公开(公告)号：US09968688B2

公开(公告)日：2018-05-15

申请号：US14539415

申请日：2014-11-12

申请人： Verily Life Sciences LLC

发明人： Alberto Clemente Vitari ,  Joshua Simon Klein ,  Jerrod Joseph Schwartz ,  Andrew Homyk ,  Marija Pavlovic

IPC分类号： A61B5/05 ,  A61K47/48 ,  A61K49/00 ,  A61K47/30 ,  A61M5/00 ,  A61B5/00 ,  G01R33/56 ,  A61B5/145 ,  A61K49/18 ,  A61K51/12 ,  A61B8/08 ,  A61B6/00

CPC分类号： A61K47/6921 ,  A61B5/0071 ,  A61B5/0515 ,  A61B5/14546 ,  A61B5/681 ,  A61B6/481 ,  A61B8/481 ,  A61K47/30 ,  A61K47/61 ,  A61K47/62 ,  A61K47/6849 ,  A61K47/6851 ,  A61K47/6923 ,  A61K47/6929 ,  A61K49/0002 ,  A61K49/0004 ,  A61K49/1824 ,  A61K51/1244 ,  A61M5/007 ,  G01R33/5601

摘要： A system is provided which includes nanoparticle conjugates configured to bind with a tumor cell, the nanoparticle conjugate comprising a nanoparticle, at least one targeting entity bound to the nanoparticle, and at least one shielding entity that shields at the at least one targeting entity, the nanoparticle, or both; a body-mountable device mounted on an external surface of a living body and configured to detect a tumor cell binding response signal transmitted through the external surface, wherein the tumor cell binding response signal is related to binding of the nanoparticle conjugates with one or more tumor cells; and a processor configured to non-invasively detect the one or more tumor cells based on the tumor cell response signal. Nanoparticle conjugates and methods for use for treating or imaging tumor cells are also provided.

公开(公告)号：US20180117217A1

公开(公告)日：2018-05-03

申请号：US15803132

申请日：2017-11-03

申请人： ANTEROGEN CO., LTD

发明人： Sung-Koo LEE ,  Mihyung KIM

IPC分类号： A61L27/38 ,  C12N5/0775 ,  A61K38/39 ,  A61K47/30 ,  A61L27/52 ,  C12N5/071 ,  C12N5/00 ,  A61P17/00 ,  A61L27/54

CPC分类号： A61L27/3813 ,  A61K9/0014 ,  A61K9/70 ,  A61K38/39 ,  A61K47/30 ,  A61L27/3834 ,  A61L27/52 ,  A61L27/54 ,  A61L2300/20 ,  A61L2300/64 ,  A61P17/00 ,  C12N5/0062 ,  C12N5/0068 ,  C12N5/0625 ,  C12N5/0665

摘要： Provided are a composition and a sheet, including a mesenchymal stem cells-hydrogel-biodegradable support or a mesenchymal stem cells-hydrogel-nondegradable support and a preparing method thereof. More specifically, in the sheet including a mesenchymal stem cells-hydrogel-biodegradable support or a mesenchymal stem cells-hydrogel-nondegradable support according to the present invention, the high-active mesenchymal stem cells may be applied to a wounded part of a patient with epidermolysis bullosa as it is without isolation using proteases, and in the culturing, an extracellular matrix such as collagen, laminin, fibronectin, and elastin secreted from the mesenchymal stem cells is wholly present on the hydrogel to have an advantageous effect that skin reproduction and re-epithelization abilities are significantly excellent as compared with conventional dressing agents used for epidermolysis bullosa.

公开(公告)号：US09950079B2

公开(公告)日：2018-04-24

申请号：US14844561

申请日：2015-09-03

申请人： International Business Machines Corporation

发明人： Dylan J. Boday ,  Jeannette M. Garcia ,  James L. Hedrick ,  Rudy J. Wojtecki

IPC分类号： A61K47/48 ,  A61K47/20 ,  A61K47/30 ,  A61K49/00 ,  C08G73/02 ,  A61K47/69 ,  A61K47/56

CPC分类号： A61K47/59 ,  A61K47/20 ,  A61K47/56 ,  A61K47/6923 ,  A61K47/6929 ,  A61K49/0002 ,  A61K49/0017 ,  A61K49/0065 ,  C08G73/0253

摘要： A functionalized nanomaterial, such as a nanoparticle, can include a polythioaminal functionalized surface. The polythioaminal linked to the surface of the nanomaterial can be bonded to a compound such as therapeutic and/or diagnostic materials. The thiol-based linkages can be used to bond the polythioaminal to both the nanomaterial and the therapeutic and/or diagnostic materials. Polythioaminals can be prepared via reactions of triazine and dithiols. Polythioaminals thus prepared can be further modified to provide linkages to the nanomaterial and other compounds such as medicinal compound, peptides, and dyes. Nanomaterials including such compounds linked thereto via the polythioaminal can be supplied for therapeutic and/or diagnostic purposes to biological target regions.

公开(公告)号：US09913910B2

公开(公告)日：2018-03-13

申请号：US15269856

申请日：2016-09-19

申请人： Heron Therapeutics, Inc.

发明人： Steven Y. Ng ,  Hui-Rong Shen ,  Jorge Heller

IPC分类号： A61K31/439 ,  A61K31/435 ,  A61K31/46 ,  A61K31/416 ,  A61K47/30 ,  A61P1/08 ,  C07D319/04 ,  A61K47/34 ,  A61K8/85 ,  A61K8/86 ,  A61K9/00 ,  A61K9/06 ,  A61K9/16 ,  A61K31/765 ,  A61K47/10 ,  A61Q19/00 ,  A61K31/445 ,  A61K31/573 ,  A61K45/06 ,  A61Q15/00 ,  A61Q17/04

CPC分类号： A61K47/34 ,  A61K8/85 ,  A61K8/86 ,  A61K9/0014 ,  A61K9/0019 ,  A61K9/0024 ,  A61K9/06 ,  A61K9/1647 ,  A61K31/439 ,  A61K31/445 ,  A61K31/573 ,  A61K31/765 ,  A61K45/06 ,  A61K47/10 ,  A61Q15/00 ,  A61Q17/04 ,  A61Q19/00

摘要： A semi-solid delivery vehicle contains a polyorthoester and an excipient, and a semi-solid pharmaceutical composition contains an active agent and the delivery vehicle. The pharmaceutical composition may be a topical, syringable, or injectable formulation; and is suitable for local delivery of the active agent. Methods of treatment are also disclosed.

公开(公告)号：US09901526B2

公开(公告)日：2018-02-27

申请号：US15189019

申请日：2016-06-22

申请人： The Procter & Gamble Company

发明人： Anju Deepali Massey-Brooker ,  Mauro Vaccaro ,  Stefano Scialla ,  Claudia Crestini ,  Heiko Lange

IPC分类号： C11D3/37 ,  A61K8/72 ,  A61Q5/02 ,  A61Q5/12 ,  A61Q11/00 ,  A61Q19/00 ,  C07G1/00 ,  C08H7/00 ,  C09G1/00 ,  C11D3/382 ,  C08L97/00 ,  A61K8/29 ,  A61K8/31 ,  A61K8/34 ,  A61K8/368 ,  A61K8/37 ,  A61K8/41 ,  A61K8/42 ,  A61K8/44 ,  A61K8/49 ,  A61K8/60 ,  A61K8/63 ,  A61K8/64 ,  A61K8/81 ,  A61K8/898 ,  A61K47/30 ,  C11D17/06 ,  C11D3/386

CPC分类号： A61K8/72 ,  A61K8/29 ,  A61K8/31 ,  A61K8/34 ,  A61K8/342 ,  A61K8/345 ,  A61K8/368 ,  A61K8/37 ,  A61K8/416 ,  A61K8/42 ,  A61K8/44 ,  A61K8/4926 ,  A61K8/498 ,  A61K8/60 ,  A61K8/63 ,  A61K8/64 ,  A61K8/8158 ,  A61K8/898 ,  A61K47/30 ,  A61K2800/40 ,  A61Q5/02 ,  A61Q5/12 ,  A61Q11/00 ,  A61Q19/00 ,  C07G1/00 ,  C08H6/00 ,  C08L97/005 ,  C09G1/00 ,  C11D3/3757 ,  C11D3/382 ,  C11D3/38609 ,  C11D3/38618 ,  C11D3/38627 ,  C11D17/06

摘要： A consumer goods product comprising a consumer goods product ingredient and a cross-linked co-polymer of a lignin oligomer and a vinyl monomer, wherein the lignin oligomer has: (a) comprises less than 1 wt % sulphur content; (b) has a number average molecular weight (Mn) of from 800 Da to 1,800 Da; and (c) has an average number of lignin monomers of from 3 to 8.